Stock Ratings / Health Care / INBX / earnings

IMTX (44) CGEM (32) VOR (42) ODTX (46) ⌘ Pro Terminal →

Inhibrx Biosciences Inc. (INBX) Next Earnings Date & Expected ±12.5% Move

$71.78 -2.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $71.32

Inhibrx Biosciences Inc. (INBX) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.06B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INBX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Inhibrx Biosciences Inc. (NASDAQ: INBX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $71.78 (-2.54% 1D, market cap $1.06B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBX ranks #996 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INBX compare to IMTX and CGEM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INBX carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $967.3M). Among the 5-stock peer group, INBX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INBX?

▼

Per INBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002007919), Inhibrx Biosciences Inc. generated $1.3M in revenue (+550.0% YoY), -$140.1M in net income, and -$129.8M in free cash flow against $146.5M in total assets and $100.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $71.31 (-0.65%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-18% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (18/100 Composite)

🔍 WHY INBX SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+5/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+4/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$87.08+9.4% Next Q

Q2 (-2Q)

Grade E$95.30+0.4% Next Q

Q3 (-1Q)

Grade E$95.66-25% Next Q

Current

Grade E$71.78-12.2% Hist 90D α

Trajectory: E (26) → E (18)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INBX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INBX currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($101.08) and Max Pain ($75.37) forces dealer call-delta covering toward $163.05.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INBX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INBX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 18%NO 82%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$8.97 Expected Swing

MODEL EARNINGS SETUP GAUGE

INBX Quantitative Pre-Earnings Setup: 18/100

Trailing EPS: $4.25 • YoY Revenue Growth: 180%

Model Bullish Setup (18/100)Model Risk Weight (82/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$1.3M	-$140.1M	-$129.8M	52%
FY 2024	2024-12-31	$200.0K	$1.69B	-$197.0M	52%
FY 2023	2023-12-31	$1.8M	-$241.4M	-$193.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBX)

✓Walkthrough of INBX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INBX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.90%🛡️ HOLDING TREND SUPPORT

2026-11-03O $73.65H $73.65L $71.78C $71.78VOL 438.9K

RES: $163.4SUP: $65.37SMA50: $101.1SMA200: $92.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INBX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INBX Butterfly Map → + Track INBX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INBX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INBX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INBX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBX)

Health Care Rank #996 of 1016 ⚔️ IMTX vs INBX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INBX vs. IMTX, CGEM, VOR, ODTX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Inhibrx Biosciences Inc. (INBX) ranks #996 by composite RQD confidence (18/100, grade E) and #352 by equity capitalization ($1.06B). Within this direct 5-issuer industry benchmark cohort, INBX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with INBX at 18/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INBX ACTIVE Inhibrx Biosciences Inc.	E	18/100	—	—	-35.0%	-2.54%	$1.06B	Benchmark Subject
IMTX Immatics N.V.	D	44/100	—	—	—	-1.50%	$1.08B	/imtx-vs-inbx →
CGEM Cullinan Therapeutics Inc.	E	32/100	—	—	-35.0%	-2.72%	$967.3M	/cgem-vs-inbx →
VOR Vor Biopharma Inc.	D-	42/100	—	—	-35.0%	-5.88%	$1.16B	/vor-vs-inbx →
ODTX Odyssey Therapeutics Inc.	D	46/100	—	—	—	-1.46%	$939.1M	/odtx-vs-inbx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002007919

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inhibrx Biosciences Inc. (INBX) reported GAAP revenue of $1.3M (+550.0% vs. FY2024 revenue of $200.0K , and -27.8% cumulative change since FY2023) , GAAP net income of -$140.1M, operating cash flow of -$129.8M, and free cash flow of -$129.8M (+34.1% YoY). On the balance sheet, INBX closed FY2025 with $146.5M in total assets against $100.6M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.3M	-$140.1M	-$129.8M	-$129.8M	$146.5M	$100.6M
FY2024 (FY)	2024-12-31	$200.0K	$1.69B	-$194.4M	-$197.0M	$180.8M	$0
FY2023 (FY)	2023-12-31	$1.8M	-$241.4M	-$193.3M	-$193.3M	—	—

3. INBX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INBX compare to IMTX and CGEM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INBX?

Where is INBX trading relative to its 50-day, 200-day, and 52-week technical levels?

INBX last traded at $71.78 (-2.54% on volume of 438,874 shares), positioning the stock -28.99% below its 50-day simple moving average ($101.08) and -22.11% below its 200-day simple moving average ($92.15). Across its 52-week range of $57.30 to $155.29, INBX sits at the 14.8% percentile with a 14-day RSI of 32.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($62.81 to $80.75).

INBX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is INBX's next earnings date?

Based on SEC filing cadence, Inhibrx Biosciences Inc. (INBX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is INBX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for INBX, spanning a range between $62.81 and $80.75.

Direct Sub-Reports: INBX RQD Cockpit INBX 12M Forecast INBX Earnings & Move INBX Dividends & DRIP INBX Insiders & 13F INBX Whale Options INBX Profit Sankey INBX News & Why

ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INBX — Inhibrx Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:30:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 18, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across its five pillars (each scored out of 20), the rating shows weakness throughout:

Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -11.98%. For a prospective investor, this means the business is not currently generating returns on invested capital, and free cash flow is negative relative to the market value.
Whale 13F Flow: 4 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The low score signals weak institutional support in the source data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider conviction signals in the data.
Macro Regime Fit: 3 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock moves in line with the broad market by this measure; the low score reflects weak fit with the current regime per the rating.
Forensic Balance Sheet: 3 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 8.5. These readings point to elevated financial distress risk as measured by the rating.

Taken together, the rating frames the stock as high-risk on a fundamental and forensic basis. Any upside a prospective investor considers would have to come from factors outside the cash-flow and balance-sheet measures, which the source data does not otherwise develop. The rating's verdict is "Avoid."

Business

Inhibrx Biosciences Inc. (INBX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, it has a market capitalization of $1.1B. The source data does not describe its products, customers, or revenue model beyond reported revenue figures in the financials section.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1.3M	$-135.0M	$-140.1M	N/A	$-129.8M	$124.2M	$100.6M
FY 2024	$0.2M	$-331.4M	$1687.6M	N/A	$-197.0M	$152.6M	$0.0M
FY 2023	$1.8M	$-219.2M	$-241.4M	N/A	$-193.3M	N/A	N/A

Per the SEC financials, operating losses appear in every reported period, and FY 2025 net margin and operating margin are both -60% per the market data. Gross margin is 0%. ROIC is -35%, and the Roarable RQD rating cites an Altman Z-Score of 0.2 and a Piotroski F-Score of 3/9. Per the Roarable RQD rating, Debt/Equity is 8.5. The FY 2024 net income figure of $1687.6M is positive while operating income is -$331.4M; the source data does not explain this divergence.

Recent Catalysts & News Wire Analysis

Recent news items in the source data, all relating to INBX:

Market action: A report on INBX stock "looking hard to pin down" at its current price (marked YELLOW, MARKET WIRE).
Price decline (GREEN, CATALYST): A Moomoo headline states the stock is "Down Over 26%, On Track for Record Percent Decrease."
Conference participation (YELLOW, MARKET WIRE): A PR Newswire release announces participation in upcoming scientific conferences.
Insider purchase (YELLOW, MARKET WIRE): An Investing.com headline reports that the CEO bought over $848k in company stock.
Pipeline credibility (YELLOW, MARKET WIRE): A Yahoo Finance piece questions whether global data reframes the late-stage pipeline credibility.
Conference data presentations (GREEN, CATALYST): A Simply Wall St piece discusses how the bull case could change following conference data presentations.

The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals. The source data does not specify the content of the pipeline data, conference presentations, or the nature of the late-stage pipeline.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is "NONE," with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. A prospective investor should note that the absence of mapped dependencies means second-order ripple effects cannot be assessed from the provided sources. The conference data and pipeline items in the news flow are the main points to monitor for any read-through, but the source data does not connect them to specific counterparties.

Open Questions

What are the specific pipeline assets, indications, and data results referenced in the late-stage pipeline and conference headlines?
What explains the FY 2024 net income of $1687.6M alongside an operating loss of $331.4M, and what are the drivers of the FY 2025 $100.6M debt position?
What is the cash runway implied by FY 2025 cash of $124.2M against FCF of $-129.8M?
What are the P/E, EPS, and EV/EBITDA values once earnings are positive, if ever, given the EPS field is N/A across reported periods?
Who are the holders behind the 13F, Form 4, and Congressional flows the rating references, and what are their positions?

INBX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Inhibrx Biosciences Inc. (INBX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INBX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 15h ago

Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price

Yahoo Finance report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Moomoo • 18h ago

Inhibrx Biosciences Down Over 26%, On Track for Record Percent Decrease -- Data Talk

Moomoo report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE PR Newswire • 21h ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

PR Newswire report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Inhibrx CEO Mark Lappe buys over $848k in company stock

Investing.com report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?

Yahoo Finance report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

Learn Why The Bull Case For Inhibrx Biosciences Stock Could Change Following Conference Data Presentations

Simply Wall St report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported.

Stock Titan report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INBX Bull vs. Bear Conversation Board — What's Your Call at $71.78?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INBX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $64.81 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is INBX (E • RQD 18/100) a Buy at $73.65?

Welcome to the INBX (Inhibrx Biosciences Inc.) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $58.92 (-20.0%)

Spot @ $73.65

Pump the brakes on INBX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INBX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Inhibrx Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $90.59 (+23.0%)

Spot @ $73.65

INBX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INBX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $73.65 (52-wk range $57.30 - $155.29), any beat on forward guidance forces shorts and underweight funds to chase.